This analysis from the Jackson Heart Study tested whether long‑term or cumulative exposure to major cardiometabolic risk factors offers prognostic information for cardiovascular disease (CVD) events beyond a single measurement taken later in life. The authors focused on three widely measured risk markers: systolic blood pressure (SBP), low‑density lipoprotein cholesterol (LDL‑C), and fasting plasma glucose (FPG). The rationale is that cumulative burden over time may better capture pathophysiologic exposure than an isolated value.
Study population and exposure window
Investigators included all Jackson Heart Study (JHS) participants who had measurements of SBP, LDL‑C, and FPG at Exam 1 (2000–2004) and Exam 3 (2009–2013) and who were alive at 8 years of follow‑up after Exam 1. The analytic sample comprised 3,188 participants; mean age was 54 years and 64% were women.
Calculation of cumulative exposures
The team calculated 8‑year cumulative exposures for each risk factor as the area under the trajectory (AUC) using all available measurements from Exams 1, 2, and 3. Exposures were centered and scaled to allow comparability across risk factors.
Outcomes and follow‑up
Adjudicated cardiovascular events evaluated separately were coronary heart disease (CHD), stroke, and heart failure (HF). Events occurring after the 8‑year exposure period were ascertained through December 31, 2016.
Statistical analysis
Conditional Cox regression models were constructed separately for each risk factor. Each model included three primary independent variables: the 8‑year cumulative exposure (AUC), the respective 8‑year value, and baseline (Exam 1) covariates. Reported effect estimates were adjusted hazard ratios (aHRs) expressed per SD of the scaled cumulative exposure, with the corresponding units provided in the manuscript for interpretability.
Cohort characteristics
Among the 3,188 eligible JHS participants, mean age was 54 years and 64% were women. The analysis used repeated measurements from Exams 1–3 to derive cumulative exposures over the first 8 years.
Associations with coronary heart disease
Higher cumulative exposures to SBP and LDL‑C were independently associated with greater risk of subsequent CHD after adjustment for covariates and the concurrent 8‑year value. Reported adjusted hazard ratios (aHR) per SD increase in cumulative exposure were 1.37 per 136 mmHg‑years for SBP (95% CI 1.09–1.71) and 1.56 per 309 mg/dL‑years for LDL‑C (95% CI 1.02–2.37).
Associations with heart failure
Higher cumulative exposure to SBP and FPG were associated with increased risk of HF after adjustment. The reported aHRs per SD of cumulative exposure were 1.15 per 136 mmHg‑years for SBP (95% CI 1.04–1.27) and 1.10 per 262 mg/dL‑years for FPG (95% CI 1.02–1.18).
Associations with stroke
For stroke, the analysis found that only the single 8‑year value (the concurrent measurement at the end of the exposure window), and not the cumulative exposure, was associated with stroke risk after full adjustment.
Comparability and scaling
Exposures were centered and scaled so hazard ratios reflect a per‑SD increase in the cumulative AUC for each risk factor. Units reported in the source (mmHg‑years for SBP, mg/dL‑years for LDL‑C and FPG) are provided with the aHRs to aid clinical interpretation.
In this cohort of African American participants from the Jackson Heart Study, greater cumulative exposure over 8 years to SBP, LDL‑C, and FPG was associated with selected subsequent CVD outcomes after adjusting for covariates and concurrent values. Specifically, cumulative SBP and LDL‑C exposures added prognostic information for CHD, while cumulative SBP and FPG exposures were associated with HF. By contrast, stroke risk was linked to the 8‑year single measurement rather than cumulative exposure in fully adjusted models.
The authors conclude that measuring cumulative exposure to common cardiometabolic risk factors may provide additional information on risk for CHD and HF compared with single later‑life measurements. This finding supports the concept that integrated exposure over time captures clinically relevant burden that may be missed by point estimates.
Note on peer review and clinical use
This report is posted as a medRxiv preprint and has not been peer reviewed; the authors note it should not be used to guide clinical practice without further validation.
Ethical oversight and consent
The Jackson Heart Study received institutional review board approvals from Jackson State University, Tougaloo College, and the University of Mississippi Medical Center. All participants provided written informed consent.
Data access
Jackson Heart Study data are available through the NHLBI BioLINCC repository, dbGaP, and by request to the JHS Coordinating Center for investigators with approved proposals. Specific data access links given in the source include BioLINCC, dbGaP, and the Jackson Heart Study Coordinating Center.
Competing interests
The authors declared no competing interests in the source article.
Limitations reported or not reported
The source article text provided does not list an explicit limitations section in the abstract; additional limitations or sensitivity analyses, if present in the full manuscript, were not reported in the provided source excerpt.